


## (±)-8-Prenylnaringenin

Cat. No.:	HY-126109
CAS No.:	68682-02-0
Molecular Formula:	C <sub>20</sub> H <sub>20</sub> O <sub>5</sub>
Molecular Weight:	340.37
Target:	Estrogen Receptor/ERR; Apoptosis
Pathway:	Vitamin D Related/Nuclear Receptor; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	(±)-8-Prenylnaringenin, a natural prenylated flavonoid, is a potent phytoestrogen. (±)-8-Prenylnaringenin is an orally active selective estrogen receptor modulator (SERM) (Estrogen Receptor/ERR) that inhibits ER $\alpha$ and ER $\beta$ with IC <sub>50</sub> s of 57 nM and 68 nM, respectively. (±)-8-Prenylnaringenin has anticancer effects, and can be used for osteoporosis research <sup>[1][2]</sup> .									
<b>IC<sub>50</sub> &amp; Target</b>	ER $\alpha$ 57 nM (IC <sub>50</sub> )	ER $\beta$ 68 nM (IC <sub>50</sub> )								
<b>In Vitro</b>	<p>In rabbit bone marrow cells, (±)-8-Prenylnaringenin inhibits the formation and induces apoptosis of Osteoclasts to a greater extent than naringenin. (±)-8-Prenylnaringenin is applied to the MC3T3-E1 osteoblast cell line, where it enhances differentiation and maturation, and also inhibits the differentiation of the RAW264.7 osteoclast cell line. (±)-8-Prenylnaringenin inhibits the expression of receptor activator of nuclear factor-<math>\kappa</math>B ligand (RANKL), and leads to increased expression of osteoprotegerin<sup>[1]</sup>.</p> <p>A significant, dose-dependent inhibition of proliferation is observed in PC-3 human prostate cancer cells and UO.31 human renal carcinoma cells after exposure to (±)-8-Prenylnaringenin. In MCF-10A, a human breast cancer cell line, (±)-8-Prenylnaringenin modulates the metabolic pathways of estradiol conversion into cancer-promoting metabolites, and thereby inhibits malignant transformation<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
<b>In Vivo</b>	<p>(±)-8-Prenylnaringenin (50 mg/kg; orally gavage; once daily; for 12 days) ameliorates impaired glucose homeostasis and islet dysfunction induced by STZ treatment. (±)-8-Prenylnaringenin increases the protein expression levels of ER<math>\alpha</math> in the pancreas and liver and of fibroblast growth factor 21 in the liver<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male C57BL/6J mice (Seven-week-old) injected with Streptozotocin (STZ)<sup>[3]</sup></td> </tr> <tr> <td>Dosage:</td> <td>50 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Orally gavage; once daily; for 12 days</td> </tr> <tr> <td>Result:</td> <td>Ameliorated impaired glucose homeostasis and islet dysfunction induced by STZ treatment.</td> </tr> </table>		Animal Model:	Male C57BL/6J mice (Seven-week-old) injected with Streptozotocin (STZ) <sup>[3]</sup>	Dosage:	50 mg/kg	Administration:	Orally gavage; once daily; for 12 days	Result:	Ameliorated impaired glucose homeostasis and islet dysfunction induced by STZ treatment.
Animal Model:	Male C57BL/6J mice (Seven-week-old) injected with Streptozotocin (STZ) <sup>[3]</sup>									
Dosage:	50 mg/kg									
Administration:	Orally gavage; once daily; for 12 days									
Result:	Ameliorated impaired glucose homeostasis and islet dysfunction induced by STZ treatment.									

---

## REFERENCES

---

- [1]. Kateřina Štulíková, et al. Therapeutic Perspectives of 8-Prenylnaringenin, a Potent Phytoestrogen from Hops. *Molecules*. 2018 Mar 15;23(3):660.
- [2]. Frederik Roelens, et al. Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alpha and beta. *J Med Chem*. 2006 Dec 14;49(25):7357-65.
- [3]. Song Park, et al. Naringenin and Phytoestrogen 8-Prenylnaringenin Protect against Islet Dysfunction and Inhibit Apoptotic Signaling in Insulin-Deficient Diabetic Mice. *Molecules*. 2022 Jun 30;27(13):4227.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA